Gene therapy for Friedreich’s ataxia
Nature Medicine
2014년4월7일
A gene therapy method corrects the heart defects in a mouse model of Friedreich’s ataxia-which damages both the heart and the nervous system and leads to movement problems. These findings, published this week in Nature Medicine, have potential application for the therapy of individuals with Friedreich’s ataxia.
Individuals with Friedreich’s ataxia harbor mutations in the gene encoding frataxin, an essential mitochondrial protein, and have a variety of symptoms, including neurodegeneration, cardiomyopathy and diabetes. The major cause of mortality in these individuals is heart failure.
Using mice lacking frataxin in the heart, Helene Puccio and her colleagues demonstrate that frataxin gene therapy can correct mitochondrial metabolism and reverse heart damage, raising the possibility of a gene therapy treatment for this disease.
doi: 10.1038/nm.3510
리서치 하이라이트
-
7월7일
Public health: Tackling adolescent stressNature
-
6월23일
Scientific community: Women credited less than men in scientific paper authorshipNature
-
5월12일
Geoscience: Monitoring earthquakes at the speed of lightNature
-
5월4일
Microbiology: Bacteriophage therapy helps treat multi-drug resistant infection in an immunocompromised patientNature Communications
-
4월27일
Planetary science: Building blocks of DNA detected in meteoritesNature Communications
-
4월8일
Health: Psilocybin use associated with lower risk of opioid addictionScientific Reports